Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, Gobbi M, Carella AM, Gozzini A, Usala E, Cavazzini F, Danise P, Tiribelli M, Binotto G, Pregno P, Bocchia M, Gaidano G, Crugnola M, Bonifacio M, Avanzini P, Celesti F, Guella A, Martino B, Annunziata M, Luciano L, Stagno F, Vallisa D, Pungolino E, Iurlo A, Rambaldi A, Nardiello I, Orlandi E, Gambacorti-Passerini C, Alimena G. Breccia M, et al. Among authors: efficace f. Leuk Res. 2015 Oct;39(10):1055-9. doi: 10.1016/j.leukres.2015.07.004. Epub 2015 Jul 14. Leuk Res. 2015. PMID: 26282944 Free article.
Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes.
Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, Baccarani M, Mandelli F; GIMEMA and EORTC Quality of Life Group. Efficace F, et al. Crit Rev Oncol Hematol. 2012 Feb;81(2):123-35. doi: 10.1016/j.critrevonc.2011.02.007. Epub 2011 Mar 24. Crit Rev Oncol Hematol. 2012. PMID: 21435899 Review.
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA. Efficace F, et al. Blood. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12. Blood. 2011. PMID: 21750313 Free article.
Transfusions at home in patients with myelodysplastic syndromes.
Niscola P, Tendas A, Giovannini M, Cupelli L, Trawinska MM, Palombi M, Scaramucci L, Brunetti GA, Perrotti A, Neri B, Efficace F, Cartoni C, de Fabritiis P, Mandelli F. Niscola P, et al. Among authors: efficace f. Leuk Res. 2012 Jun;36(6):684-8. doi: 10.1016/j.leukres.2012.01.010. Epub 2012 Feb 14. Leuk Res. 2012. PMID: 22336393
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F, Sprangers M. Efficace F, et al. Ann Hematol. 2012 Sep;91(9):1371-81. doi: 10.1007/s00277-012-1458-6. Epub 2012 Apr 29. Ann Hematol. 2012. PMID: 22543826
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, Alimena G, Iurlo A, Rossi AR, Pardini S, Gherlinzoni F, Salvucci M, Tiribelli M, Vignetti M, Mandelli F. Efficace F, et al. Br J Cancer. 2012 Sep 4;107(6):904-9. doi: 10.1038/bjc.2012.348. Epub 2012 Aug 7. Br J Cancer. 2012. PMID: 22871884 Free PMC article.
273 results